#AANAM — Tysabri Lowers Serum Neurofilament Light Levels in SPMS Patients, Phase 3 Trial Finds
Treatment with Tysabri (natalizumab) lowers the levels of the biomarker serum neurofilament light chain (sNfL) in patients with secondary progressive multiple sclerosis (SPMS), according to data from a Phase 3 trial. Findings also revealed that higher levels of sNfL correlated with MS lesions and disease activity prior to starting the…